Anúncio
Anúncio
ABCL
AbCellera Biologics Inc. Common Shares
4.12
USDPatrocinado
-0.01
-0.36%
08 de jan., 11:11 UTC -5
Abrir
Relatórios de Lucros ABCL
Rácio de surpresa positiva
ABCL separação 8 de 20 últimas estimativas.
40%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.75M
/-$0.18
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-35.75%
/-5.26%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+13.94%
/+63.64%
AbCellera Biologics Inc. Common Shares earnings per share and revenue
On 06 de nov. de 2025, ABCL reported earnings of -0.19 USD per share (EPS) for Q3 25, missing the estimate of -0.17 USD, resulting in a -10.40% surprise. Revenue reached 8.96 milhão, compared to an expected 6.03 milhão, with a 48.57% difference. The market reacted with a -13.69% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.18 USD, with revenue projected to reach 5.75 milhão USD, implying an diminuir of -5.26% EPS, and diminuir of -35.75% in Revenue from the last quarter.
FAQ
What were AbCellera Biologics Inc. Common Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, AbCellera Biologics Inc. Common Shares reported EPS of -$0.19, missing estimates by -10.4%, and revenue of $8.96M, 48.57% above expectations.
How did the market react to AbCellera Biologics Inc. Common Shares's Q3 2025 earnings?
The stock price moved down -13.69%, changed from $4.53 before the earnings release to $3.91 the day after.
When is AbCellera Biologics Inc. Common Shares expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for AbCellera Biologics Inc. Common Shares's next earnings report?
Based on 10
analistas, AbCellera Biologics Inc. Common Shares is expected to report EPS of -$0.18 and revenue of $5.75M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio